Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs DHR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

SYK Overall Winner 6-Pillar Tally: SYK 4 – 2 DHR Matrix Metrics: SYK 4 – 6 DHR

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Danaher Corporation (DHR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DHR carries 48.3/100 (HOLD) at $231.54 (25.0x Forward P/E, 22.0% operating margin).

  • Composite vs. Pillar Nuance: While DHR currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 22.0% operating margin) and revenue trajectory (+7.6% vs. +8.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs DHR
SYK NYSE Head-to-Head Winner
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
DHR NYSE
Danaher Corporation
Industrial Instruments For Measurement, Display, And Control
$231.54
-0.64% 1D
Market Cap $163.3B
TTM Revenue $25.6B
Forward P/E 25.0x
Beta / 30D Vol 0.46β · 28% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 36.0 Fund 46.0 Flow 57.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.1% over 20 days), RSI 54
RSI-14: 54.4 · SMA20: $232.04 · SMA50: $223.01

6-Pillar Scorecard Institutional Category Breakdown (SYK 4 – 2 DHR)

Columns: Metric · SYK · DHR
1. Valuation Multiples SYK
Forward P/E 19.0x 25.0x
Trailing P/E 33.3x 38.4x
PEG Ratio 1.54x 1.34x
EV / Revenue 5.0x 7.2x
2. Growth & Scale DHR
Revenue Growth (YoY) +7.6% +8.3%
Earnings Growth (YoY) -11.7% +37.8%
TTM Revenue (USD) $26.3B $25.6B
Market Cap $118.9B $163.3B
3. Profitability & Quality SYK
Gross Margin 65.7% 59.4%
Operating Margin 24.0% 22.0%
Net Profit Margin 13.8% 16.9%
Return on Equity (ROE) 16.0% 8.2%
4. Balance Sheet & Cash Flow DHR
Cash Generation (TTM) $4.57B $5.73B
Cash Flow Margin 17.4% 22.4%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $20.8B Net Debt (0.49x D/E)
Dividend Yield 1.10% 0.65%
5. Options & Positioning SYK
Options Structure Phase SURGE BREAKOUT
Current IV / %ile 28.1% (5th %ile) 54.8% (38th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.50x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 37.4% of Rev ($9.58B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (4) vs DHR (6)
Institutional Metric SYK DHR Criterion Row Edge
Market Capitalization
Scale
$118.9B $163.3B Larger Scale DHR
Trailing P/E Ratio
Valuation
33.3x 38.4x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 25.0x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+7.6% +8.3% Higher Growth DHR
Operating Margin (TTM)
Profitability
24.0% 22.0% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 16.9% Higher Margin DHR
Return on Equity (ROE)
Capital Efficiency
16.0% 8.2% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 86% ($161–$243) Stronger Trend DHR
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.46β · 28% Vol Lower Realized Risk DHR
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite DHR
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $25.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 59.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 1.34x PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $5.73B ($20.8B Net Debt (0.49x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYK +4.38 pp
SYK: +5.47% · DHR: +1.09%
3M Horizon DHR +22.22 pp
SYK: -6.21% · DHR: +16.01%
6M Horizon DHR +42.08 pp
SYK: -0.78% · DHR: +41.3%
1Y Horizon DHR +21.44 pp
SYK: -16.77% · DHR: +4.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue DHR Revenue SYK Op. Margin DHR Op. Margin Margin Leader
FY2018 $13.6B $17.1B 18.7% 17.9% SYK
FY2019 $14.9B $17.9B 18.2% 18.3% DHR
FY2020 $14.3B $22.3B 15.5% 19.0% DHR
FY2021 $17.1B $24.8B 15.1% 25.7% DHR
FY2022 $18.4B $26.6B 15.4% 28.3% DHR
FY2023 $20.5B $23.9B 19.0% 21.8% DHR
FY2024 $22.6B $23.9B 16.3% 20.4% DHR
FY2025 $25.1B $24.6B 19.5% 19.1% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DHR BREAKOUT
69d in phase · OBV ACCUMULATION
Current IV 54.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DHR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
DHR Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $163.3B market capitalization and 22.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($9.58B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs DHR Key Questions & Quantitative Answers

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Danaher Corporation (DHR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DHR carries 48.3/100 (HOLD) at $231.54 (25.0x Forward P/E, 22.0% operating margin). Composite vs. Pillar Nuance: While DHR currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 22.0% operating margin) and revenue trajectory (+7.6% vs. +8.3% YoY).

DHR leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with DHR at +8.3% YoY revenue growth and +37.8% YoY earnings growth on $25.6B TTM revenue (59.4% gross margin, 22.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while DHR shifted +44.1%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 37.4% of Rev ($9.58B) (0 disclosures) for DHR.

SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas DHR trades at 25.0x Forward P/E, 38.4x Trailing P/E, 1.34x PEG, and 7.2x EV/Revenue (22.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus DHR (8.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, DHR carries 54.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.46β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.